Neoleukin Therapeutics Inc

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Holly K. Vance as General Counsel.

Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel

SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of a preclinical data abstract on its lead therapeutic candidate, NL-201, at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020) taking place November 9 to November 14, 2020 in a virtual format.

Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)

AstraZeneca

Biogen

Momenta Pharmaceuticals

Perrigo

Relmada Therapeutics Inc

Sanofi

Supernus Pharmaceuticals

Takeda Pharmaceutical

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Pharmaceutical Stocks for Q4 2020

SEATTLE, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 9:30 a.m. Eastern Time.

Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Neoleukin (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Neoleukin (NLTX) Upgraded to Buy: What Does It Mean for the Stock?

Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2020 Results - Earnings Call Transcript

SEATTLE, Aug.  12, 2020  (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ending June 30, 2020 and a midyear corporate update.

Neoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate Update

SEATTLE, Aug.  06, 2020  (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that management will participate in a fireside chat at the virtual Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 8:30 a.m. Eastern Time.

Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conference

SEATTLE, Aug.  05, 2020  (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report second quarter 2020 financial results on Wednesday, August 12, 2020 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows:

Neoleukin Therapeutics to Host Second Quarter 2020 Financial Results & Corporate Update Conference Call and Webcast on August 12, 2020

The drug developer has an intriguing technology platform and expects to enter clinical trials before the end of 2020, but there are a few things investors cannot overlook.

Is Neoleukin Therapeutics a Buy?

DURECT

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

Is It Too Late to Buy These 3 Pharmaceutical Stocks?

Neoleukin (NLTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Neoleukin (NLTX) Moves to Buy: Rationale Behind the Upgrade

The development-stage drug company announced the pricing of a public offering of common stock.

Here's Why Neoleukin Therapeutics Dropped Today

SEATTLE, July  02, 2020  (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 3,262,471 shares of its common stock at a price to the public of $15.25 per share. In addition, and in lieu of common stock, Neoleukin is offering to certain investors pre-funded warrants to purchase up to an aggregate of 1,737,529 shares of common stock at a purchase price of $15.249999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.000001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $76.2 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Neoleukin. The offering is expected to close on or about July 7, 2020, subject to customary closing conditions.  Neoleukin has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock in connection with the public offering. All of the securities are being offered by Neoleukin.

Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering

SEATTLE, July  01, 2020  (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to 5.0 million shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering.  Neoleukin expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. All of the securities are being offered by Neoleukin. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Neoleukin Therapeutics Announces Proposed Public Offering

Neoleukin Therapeutics (NLTX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Neoleukin Therapeutics (NLTX) Looks Good: Stock Adds 9.4% in Session

- NL-201 demonstrates durable antitumor activity in animal tumor models -  - NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo -  - Conditional activation of de novo proteins using split molecule technology may increase therapeutic index -  - Company to host Investor R&D Showcase Tuesday, June 23 at 3:30 p.m. PT / 6:30 p.m. ET -

Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II

Amphastar Pharma

Cronos Group

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2020.

Top Pharmaceutical Stocks for Q3 2020

SEATTLE, June  01, 2020  (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Erin Lavelle to the company’s Board of Directors. Ms. Lavelle has more than 20 years of strategic and operational leadership experience in the biopharmaceutical industry and most recently served as Chief Operating Officer for Alder Biopharmaceuticals, Inc. She succeeds Sean Nolan, who will be stepping down from the Board. Mr. Nolan has served as a director of Aquinox Pharmaceutics since 2015 and remained on the Neoleukin Board after the merger in August 2019.

Neoleukin Therapeutics Announces Appointment of Erin Lavelle to Board of Directors

Neoleukin (NLTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Neoleukin (NLTX) Moves to Strong Buy: Rationale Behind the Upgrade

Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2019 Results - Earnings Call Transcript

SEATTLE, Feb.  25, 2020  (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Robert Ho as Chief Financial Officer, effective March 16, 2020. Kamran Alam, interim CFO of Neoleukin Therapeutics, will continue as a senior strategic advisor to assist in transition activities.

Neoleukin Therapeutics Announces Appointment of Robert K. Ho as Chief Financial Officer

XPEL

Here are three stocks that have broken out of above resistance and are looking higher: Neoleukin Therapeutics, Inc.

3 Breakout Stocks To Watch

SEATTLE, Dec.  20, 2019  (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the closing of its public offering of 10,263,750 shares of its common stock at a public offering price of $8.40 per share, which includes the exercise in full of the underwriters’ option to purchase 1,338,750 shares of common stock.The aggregate gross proceeds to Neoleukin, before deducting underwriting discounts and commissions and estimated offering expenses payable by Neoleukin, were approximately $86.2 million.

Neoleukin Therapeutics  Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEATTLE, Dec.  17, 2019  (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 8,925,000 shares of its common stock at a price to the public of $8.40 per share. The aggregate gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Neoleukin. The offering is expected to close on or about December 20, 2019, subject to customary closing conditions. Neoleukin has also granted the underwriters a 30-day option to purchase up to an additional 1,338,750 shares of common stock in connection with the public offering. All of the shares are being offered by Neoleukin.

News for Neoleukin Therapeutics Inc Stock (NLTX)